

AUSTRALIA
PATENTS ACT 1990
NOTICE OF ENTITLEMENT

We, **Ethical Pharmaceuticals Limited**, the applicant/Nominated Person in respect of Application No. 32636/93 state the following:-

The Nominated Person is entitled to the grant of the patent because the Nominated Person would, on the grant of a patent for the invention to the inventor, be entitled to have the patent assigned to the Nominated Person.

The Nominated Person is entitled to claim priority from the application listed in the declaration under Article 8 of the PCT because the Nominated Person made the application listed in the declaration under Article 8 of the PCT, and because that application was the first application made in a Convention country in respect of the invention.

DATED this FIFTH day of AUGUST 1994



.....
a member of the firm of
DAVIES COLLISON
CAVE for and on behalf
of the applicant(s)

(DCC ref: 1674330)



AU9332636

(12) PATENT ABRIDGMENT (11) Document No. AU-B-32636/93
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 659529

(54) Title
PHARMACEUTICAL COMPOSITIONS CONTAINING NIFEDIPINE AND PROCESS FOR THE
PREPARATION THEREOF

International Patent Classification(s)
(51)⁵ A61K 031/44 A61K 009/16 A61K 009/20 A61K 009/48
A61K 047/32

(21) Application No. : 32636/93 (22) Application Date : 12.01.93

(87) PCT Publication Number : WO93/13773

(30) Priority Data

(31) Number	(32) Date	(33) Country
9200607	13.01.92	GB UNITED KINGDOM

(43) Publication Date : 03.08.93

(44) Publication Date of Accepted Application : 18.05.95

(71) Applicant(s)
ETHICAL PHARMACEUTICALS LIMITED

(72) Inventor(s)
DAVID TRIGGER

(74) Attorney or Agent
DAVIES COLLISON CAVE , 1 Little Collins Street, MELBOURNE VIC 3000

(56) Prior Art Documents
US 5108757
EP 0385582
EP 0410422

(57) Claim

1. A slow-release pharmaceutical composition which comprises particles of a finely divided pharmaceutically acceptable water soluble carrier coated with a mixture of nifedipine with polyvinylpyrrolidone or a copolymer of N-vinylpyrrolidone and vinyl acetate, and a pharmaceutically acceptable acrylic based polymer, the weight ratio of the polyvinylpyrrolidone or N-vinylpyrrolidone and vinyl acetate copolymer to the content of nifedipine being in the range of from 1:1 to 1:10 and the weight ratio of the acrylic based polymer to the content of nifedipine being in the range of from 1:4 to 1:20.

13. A process for the preparation of a pharmaceutical composition which contains nifedipine as the active agent, polyvinylpyrrolidone or a copolymer of N-vinyl pyrrolidone and vinyl acetate, and a pharmaceutically acceptable

(11) AU-B-32636/93
(10) 659529

-2-

acrylic based polymer, the weight ratio of the polyvinylpyrrolidone or copolymer of N-vinyl-pyrrolidone and vinylacetate to the content of nifedipine being in the range of from 1:1 to 1:10 and the weight ratio of the acrylic based polymer to the content of nifedipine being in the range of from 1:4 to 1:20, which process comprises dissolving nifedipine, polyvinylpyrrolidone or the copolymer of N-vinylpyrrolidone and vinyl acetate, and the pharmaceutically acceptable acrylic based polymer in a suitable solvent to form a solution, coating particles of a finely divided pharmaceutically acceptable water soluble carrier which is insoluble in the solvent with said solution and evaporating the solvent from the coated carrier particles.

OPI DATE 03/08/93 APPLN. ID 32636/93
AOJP DATE 14/10/93 PCT NUMBER PCT/GB93/00055



AU9332636

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/44, 9/16	A1	(11) International Publication Number: WO 93/13773 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/GB93/00055 (22) International Filing Date: 12 January 1993 (12.01.93) (30) Priority data: 9200607.1 13 January 1992 (13.01.92) GB (71) Applicant (for all designated States except US): ETHICAL PHARMACEUTICALS LIMITED [GB/GB]; Cambridge Business Park, Angel Drive, Ely, Cambs. CB7 4EE (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): TRIGGER, David [GB/GB]; The Old School House, The Green, Shouldham, King's Lynn, Norfolk PE33 0BY (GB). (74) Agent: PAGET, Hugh, C., E.; Mewburn Ellis, 2 Cursitor Street, London EC4A 1BQ (GB).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO, RU, SD, SE, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published With international search report. → Gemini House Bartholomew's Walk Cambridgeshire Business Park Ely, Cambridgeshire CB7 4EA United Kingdom 659529 
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING NIFEDIPINE AND PROCESS FOR THE PREPARATION THEREOF (57) Abstract Compositions and processes for their preparation are provided in which nifedipine is coated onto a water soluble carrier in a mixture with polyvinylpyrrolidone or a copolymer of N-vinylpyrrolidone and vinyl acetate and a pharmaceutically acceptable acrylic based polymer. The ratio of the polyvinylpyrrolidone or N-vinylpyrrolidone/vinyl acetate copolymer to the content of nifedipine is in the range of from 1:1 to 1:10 and the ratio of the acrylic based polymer to the content of nifedipine is in the range of from 1:4 to 1:20. Compositions are provided which are suitable for once-a-day administration of nifedipine.		

See folio 7

PHARMACEUTICAL COMPOSITIONS CONTAINING NIFEDIPINE
AND PROCESS FOR THE PREPARATION THEREOF

INTRODUCTION

Technical Field

The present invention relates to pharmaceutical compositions containing nifedipine and to a process for the preparation thereof. In particular the present invention relates to a slow release pharmaceutical formulation containing nifedipine which provides for a regular and
5 prolonged release pattern upon administration and, in its most preferred form, may be administered once a day. The invention also relates to a process for the preparation thereof.

10 Background to the invention

The drug nifedipine is currently used in the form of rapid release and comparatively slow release pharmaceutical dosage forms for the treatment, respectively, of acute angina and chronic hypertension.
15 It appears that, for the acute treatment of angina, it is desirable quickly to attain relatively high nifedipine concentrations in plasma and this requirement is currently served by a preparation consisting of a solution of nifedipine in low molecular weight polyethylene glycol
20 contained within soft gelatin capsules. For the treatment of hypertension it appears that it is more desirable to maintain plasma nifedipine concentrations within a much lower concentration range. Modified release preparations

of the substance are available for this purpose, although they mostly still require multiple daily doses to be taken which is both a clinical disadvantage in that symptomatic control of the condition may not be optimised and a
5 disadvantage from the patient's point of view. The inconvenience of taking a dosage more than once per day may affect compliance with the dosage regime, also leading to poor clinical performance.

The reason for the two significantly different
10 types of formulation is that nifedipine per se is very poorly soluble in water. Because of this many of the patent specifications on controlled release systems of nifedipine describe means of actually enhancing, rather than suppressing, the solubility of nifedipine.

15 Thus, in European Patent No. 0047899 (corresponding to Canadian Patent No. 1180277) control of the dissolution of nifedipine is achieved by processing the material to give it a large specific surface area of 0.5 to 6m²/g. The specification discloses the production of fine
20 nifedipine crystals by grinding and screening but not by any other means.

Similarly, in PCT/EP85/00481 the control of nifedipine dissolution is achieved by limiting its specific surface area to 0.1 to 0.42m²/g and coating the
25 nifedipine crystals, in admixture with an equal quantity of a filler, onto inert spheroids by means of suitable binders.

Further enhancement of the dissolution of

nifedipine is achieved by processing the material to form a solution adsorbed onto a solid base (as in British Patent No. 1,456,618), or to form a solid solution (also known as a co-precipitate) with high molecular weight polyethylene glycol (European Patent Application No. 0220760) or an ester or ether of polyethylene glycol (European Patent Application No. 0249587) or with other selected materials, including polyvinylpyrrolidone (British Patent No. 1,579,818).

10 This ability of polyvinylpyrrolidone to enhance the solubility characteristics of certain materials by forming coprecipitates with them is now fairly well documented. It is also generally accepted that in order to form such coprecipitates the amount of
15 polyvinylpyrrolidone used must be in excess of the amount of active material.

 In our European Patent No. 385582 we describe pharmaceutical compositions in which polyvinylpyrrolidone in an amount less than the amount of nifedipine actually
20 significantly slows the dissolution of nifedipine from the finished solid dosage form. More specifically, EP 385582 discloses a pharmaceutical composition which comprises particles of a finely divided pharmaceutically acceptable water soluble carrier coated with microparticles of
25 nifedipine, the majority of which have a particle size of 100 micrometres or less, in the presence of polyvinylpyrrolidone, the polyvinylpyrrolidone being present in an amount of from 10 to 90% by weight based on

the weight of the nifedipine.

We have found that these compositions can provide a slow release of nifedipine over a period of up to about 12 hours, i.e. to provide a potential composition for
5 twice-daily administration of nifedipine. Attempts to slow the release of nifedipine from the tablets by increasing the amount of polyvinylpyrrolidone were unsuccessful and the addition of other materials to the system diluted the effect of polyvinylpyrrolidone and thus only succeeded in
10 speeding the release of nifedipine from the compositions.

Acrylic resins have previously been used in tablet compositions. However, they have been used in much larger relative amounts than in the present invention, and the resulting compositions have short release profiles.

15 GB 2229095 describes compositions containing nifedipine in crystalline form, hydrophilising agent and retarding agent. Polyvinylpyrrolidone is mentioned as a hydrophilising agent, but no example is given. For sustained release composition, the amount of retarding
20 agent required is in the range 0.2 to 1.5 parts by weight relative to the nifedipine content. In this document, polyvinyl butyrate is preferred as the retarding agent because a smaller amount is said to be required than if an acrylic polymer is used.

25 In WO86/01717 nifedipine is coated by spraying onto sucrose granules which have first been wetted with polyvinylpyrrolidone. The coated granules are then wetted with Eudragit (an acrylic polymer) in a ratio of 35 parts

Sugimoto et al. in Drug Development and Industrial Pharmacy (1980), 6, p137-160 and Chem. Pharm. Bull (1982) 30 (12) p4479-2288 discuss the use of polymeric materials to increase the solubility of PVP in co-precipitates, resulting in nifedipine formulations with rapid release characteristics. Where PVP is mentioned, the amount of PVP used in the co-precipitates of nifedipine with PVP is always in amounts in excess of the nifedipine content.

There is a need for a potential product for once-daily administration of nifedipine. We have surprisingly
15 discovered that the addition of an acrylic resin to certain pharmaceutical compositions, for example those disclosed in our earlier European Patent No. 385582 results in compositions that can become useful as once a day treatments.

20 The present invention provides a ^{slow-release} pharmaceutical composition which comprises particles of a finely divided pharmaceutically acceptable water soluble carrier coated with a mixture of nifedipine with polyvinylpyrrolidone or a copolymer of N-vinyl-pyrrolidone and vinyl acetate, and a

25 pharmaceutically acceptable acrylic based polymer, the weight ratio of the polyvinylpyrrolidone or copolymer of N-vinylpyrrolidone and vinyl acetate copolymer to the content of nifedipine being in the range of from 1:1 to



1:10 and the weight ratio of the acrylic based polymer to the content of nifedipine being in the range of from 1:4 to 1:20.

The present invention also includes within its scope a process for the preparation of the pharmaceutical compositions as defined above, which process comprises forming a solution of nifedipine, polyvinylpyrrolidone or a copolymer of N-vinylpyrrolidone and vinyl acetate and a pharmaceutically acceptable acrylic based polymer (which may for example be an acrylic resin) in a suitable solvent, coating particles of a finely divided pharmaceutically acceptable water soluble carrier which is insoluble in the solvent with the solution and evaporating the solvent from the surface of the coated carrier particles.

Throughout the present specification the copolymer of N-vinylpyrrolidone and vinyl acetate will be referred to as an "N-vinylpyrrolidone copolymer". A suitable example of such a copolymer is Kollidon VA 64 obtainable from BASF.

All ratios are by weight. Preferably, the ratio of the acrylic based polymer to the content of nifedipine is in the range 1:5 to 1:12. Most preferably this ratio is in the range 1:6 to 1:10.

It is further preferable that the ratio of the content of polyvinylpyrrolidone or N-vinylpyrrolidone copolymer in the composition to the content of nifedipine is in the range 1:2 to 1:8. Very preferably this ratio is in the range 1:2 to 1:5. A particularly advantageous ratio

is 1:4.

In a highly preferred form of the invention the nifedipine is present in a predominantly amorphous form in the composition. We believe that the composition is a
5 highly amorphous layer of a solid solution of polyvinylpyrrolidone (or N-vinylpyrrolidone copolymer), nifedipine and acrylic based polymer coated on the carrier, as distinct from the nifedipine being in crystalline form. However, the invention is not be be
10 limited by theoretical considerations and the possibility is not excluded that some of the nifedipine may have some crystalline structure.

In our own SEM (scanning electron microscope) studies, no crystalline nifedipine was seen.

15 Preferably the amount of drug released from a composition according to the invention in an in vitro dissolution test is related to time by a linear relationship better than by a square-root of time relationship.

20 Advantageously, dosage units formed from a composition of the invention can provide substantially linear release of nifedipine over 8 hours, or more.

DESCRIPTION OF SPECIFIC EMOIDIMENTS

25 The pharmaceutically acceptable water soluble carrier may be any carrier which is normally used in the preparation of pharmaceutical compositions, for example lactose, sucrose, mannose, sorbitol, or mixtures thereof.

The pharmaceutically acceptable water soluble carrier preferably has a particle size of less than 250 micrometres and preferably also has a specific surface area of greater than $0.5 \text{ m}^2/\text{gram}$.

5 Although polyvinylpyrrolidone and N-vinylpyrrolidone copolymer are known as binders for use in the preparation of various pharmaceutical compositions, these materials have, when used in the proportions herein specified and incorporated together with the acrylic based
10 polymer in the manner described, a specific effect in controlling the rate of dissolution and release of nifedipine from the coated carrier particles.

The pharmaceutically acceptable acrylic based polymer which is incorporated into the pharmaceutical
15 compositions of the present invention may be any suitable pharmaceutically acceptable acrylic based polymer. By acrylic based polymer we mean a polymer whose monomer units are primarily or entirely acrylic or allylacrylate. Low amounts e.g. up to 10% by weight of co-monomer may be
20 present. The acrylic based polymer may be cationic, non-ionic or anionic and may be, for example, a poly-acrylate, a poly-methacrylate or a copolymer of acrylic and methacrylic acid esters. Any of these may have a low content of quaternary ammonium groups. Non-ionic acrylic
25 based polymers are highly preferred, as are acrylic resins. Examples of suitable acrylic based polymers are the whole of the range sold under the trade name EUDRAGIT BY Rohm Pharma GmbH.

In carrying out the process of the present invention, the water soluble carrier may be coated with the nifedipine/polyvinylpyrrolidone/acrylic based polymer in a single stage process or in a stepwise manner. For
5 example, all of the solution may be coated onto the carrier in one stage or, alternatively and preferably, part of the solution may be coated onto the carrier and the mixture granulated and dried, followed by coating of the dry granulate with the remaining part of the solution and
10 drying and granulating the resulting mixture. This stepwise process may be performed in more than two steps.

The solvent which is used in the process of the invention must be a solvent for nifedipine, the polyvinylpyrrolidone and the acrylic based polymer, but should
15 not dissolve the pharmaceutically acceptable carrier. Examples of suitable solvents are lower aliphatic alcohols, methylene chloride or chloroform. The most preferred solvent for use is chloroform.

The solvent evaporates from the surface of the
20 coated carrier particles thus leaving nifedipine in the presence of the polyvinylpyrrolidone and the acrylic based polymer, coated onto the particles of the finely divided pharmaceutically acceptable water soluble carrier. As mentioned, it is preferred that in this coating the
25 nifedipine shows amorphous, rather than crystalline, characteristics.

The pharmaceutical composition of the present invention may be formulated into a solid unit dosage form,

such as tablets or capsules, in a conventional manner. In the preparation of such formulations conventional additives may be used such as lubricants, binders, stabilizers etc.

The pharmaceutical compositions of the present invention possess good stability and are easily reproducible. During the preparation of the compositions milling is not required and this avoids the formation of nifedipine dust.

It will be appreciated that dry milling techniques are tedious and expensive and, furthermore, that the dust from a drug such as nifedipine is potentially hazardous. The process of the present invention thus provides an economic and simple route to the production of a pharmaceutical composition comprising nifedipine.

The present invention will be further described with reference to the following Examples and the accompanying drawings, in which:-

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the rate of release of nifedipine in in vitro dissolution tests from the tablets of Examples 1 to 4;

Figure 2 illustrates mean blood levels of nifedipine attained after administration to human volunteers of one tablet as described in Example 3 in comparison with two other compositions; and

Figures 3 to 5 are SEM photomicrographs of

granules according to the invention.

EXPERIMENTAL

A. General Processing Method

Nifedipine and polyvinylpyrrolidone (PVP) were dissolved in chloroform (nominal quantity of 0.15 ml chloroform per tablet containing a nominal content of 30 mg nifedipine) and mixed using a propeller mixer. Acrylic resin (Eudragit RS 100) was dissolved in the resulting solution and mixed for ten minutes.

10 Lactose was placed in a mixer granulator and granulated with half of the nifedipine/acrylic resin solution. Mixing was continued for one minute after the addition of the solution at which time the mixer was stopped, the bowl scraped down, the mixer re-started and 15 the wet granulate mixed for a further four minutes. The resulting wet granulate was fluid bed dried for fifteen minutes at an air inlet temperature of 60°C.

Dry first-stage granulate was returned to the mixer/granulator and regranulated with the remaining 20 nifedipine/acrylic resin solution and the resulting granulate mixed for one minute. The mixer was stopped, the sides of the bowl scraped down, the mixer re-started and the wet granulate mixed for a further four minutes. The resulting wet granulate was fluid bed dried for ten 25 minutes at an air inlet temperature of 60°C.

The resulting dry granulate was screened through a 1 mm aperture stainless steel sieve and fluid bed dried at an air inlet temperature of 60°C.

Appropriate amounts of hydrogenated castor oil and purified talc to be employed as lubricant were added to the dry granulate and blended in a V-cone blender for ten minutes.

5 The resulting lubricated granulate was compressed into tablets.

Example 1

10 Preparation of composition containing acrylic polymer and nifedipine in a weight ratio of 1:12

Using the general procedure detailed in A above tablets were prepared each having the following composition:

	<u>Parts by Weight</u>
15 Nifedipine	30.0
Polyvinylpyrrolidone	7.5
Lactose	300.0
Acrylic Polymer (Eudragit RS)	2.5
Hydrogenated Castor Oil	3.5
20 Purified Talc	7.1

In vitro dissolution tests were carried out using the USP Dissolution Test Apparatus 2, employing a paddle speed of 50 rpm, operated at 37°C with 2.5% w/v aqueous sodium dodecylsulphate solution used as the dissolution test medium.

The rate of release of nifedipine from these tablets in these dissolution tests is plotted in Figure 1.

Example 2

Preparation of composition containing acrylic polymer and nifedipine in a weight ratio of 1:8.57

- 5 Using the general procedure detailed above in A tablets were prepared each having the following composition:

	<u>Parts by Weight</u>
Nifedipine	30.0
10 Polyvinylpyrrolidone	7.5
Lactose	300.0
Acrylic Polymer (Eudragit RS)	3.5
Hydrogenated Castor Oil	3.5
Purified Talc	7.1

- 15 Dissolution tests were carried out according to the procedure of Example 1 and the results are plotted in Figure 1.

Example 3

20 Preparation of composition containing acrylic polymer and nifedipine in a weight ratio of 1:6.67

- Using the general procedure detailed above in A tablets were prepared each having the following composition:

	<u>Parts by Weight</u>
25 Nifedipine	30.0
Polyvinylpyrrolidone	7.5
Lactose	300.0
Acrylic Polymer (Eudragit RS)	4.5
Hydrogenated Castor Oil	3.5
30 Purified Talc	7.1

Dissolution tests were carried out according to the procedure of Example 1B and the results are plotted in Figure 1.

5

Example 4

Preparation of composition containing acrylic polymer and nifedipine in a weight ratio of 1:4.7

Using the general procedure detailed above in A tablets were prepared each having the following
10 composition:

	<u>Parts by Weight</u>
Nifedipine	30.0
Polyvinylpyrrolidone	7.5
Lactose	300.0
15 Acrylic Polymer (Eudragit RS)	6.38
Hydrogenated Castor Oil	3.5
Purified Talc	7.1

Dissolution tests were carried out according to the procedure of Example 1 and the results are plotted in
20 Figure 1.

Table 1 presents the dissolution test data of examples 1 to 4 in table form, and shows the dissolution profile over a slightly longer period than does Fig. 1. The table also gives the time to 50% release (T_{50}) for each
25 formulation. The T_{50} values of these compositions show that they are useful once-a-day preparations. In particular the formulations of Examples 2 and 3 with T_{50} values of around 7 hours are very useful.

Example 5

Preparation of composition containing acrylic polymer and nifedipine in a weight ratio of 1:7.5

5 Using the general procedure detailed above tablets were prepared each having the following composition:

	<u>Parts by Weight</u>
Nifedipine	30.0
Polyvinylpyrrolidone	7.5
10 Lactose	300.0
Acrylic Polymer (Eudragit RS)	4.0
Hydrogenated Castor Oil	3.5
Purified Talc	7.1

15 Tablets of this Example were used in a test described below.

TABLE 1

	Time (h)	Example 1	Example 2	Example 3	Example 4
5	Dissolution test profile: mean percentage released from 6 replicate tables at time (hour)				
10	1.0			7	4
	1.5	16	10		
	2.0			15	6
	3.0	31	18	22	10
	4.0			28	14
15	4.5	48	29		
	5.0			35	19
	6.0	70	42	45	24
	7.0			52	32
	7.5	84	57		
20	8.0			62	37
	9.0		73		
	10.0			77	
	10.5		85		
	12.0			86	
25	16.0				80
	17.0				85
	T ₅₀ **	4.6	6.8	6.8	11.4

30

**T₅₀ = Time to 50% release

35 The in vitro dissolution procedure used in these tests has been shown to give results that correlate very satisfactorily with in vivo results over a wide range of release rates.

40

Example 6

Table 2 below shows the results of in vitro dissolution tests carried out as in Examples 1-4 on three development scale batches with polyvinylpyrrolidone and nifedipine in weight ratios of 1:7.9, 1:4 and 1:2.7. The acrylic polymer (Eudragit RS) in each batch formulation was

in a weight ratio of 1:6.67 with respect to nifedipine.

Batch No. 2 was equivalent to the formulation in Example 3.

5	Batch No. PVP : N ratio	1 1:7.9	2 1:4	3 1:2.7
	time (h)	% nifedipine released		
10	0.25	2	2	1
	0.5	3	4	4
	1	8	7	5
	2	13	13	11
	3	21	21	16
	4	30	26	22
15	5	36	33	26
	6	42	40	29
	7	49	48	33
	8	55	57	39

20

RELEASE CHARACTERISTICS

We found that the profile of drug release from compositions according to the present invention closely follows zero-order kinetics. This is in contrast to the prior art products for which the profile is non-linear due to diffusion controlled release of drug. The linear release profile has a significant advantage because a steady rate of supply of drug to the body will result in relatively steady blood levels. In the treatment of chronic heart conditions with nifedipine this is especially advantageous. Furthermore, the side-effects associated with the use of nifedipine may be reduced since these are often associated with peaks in the level of nifedipine in the blood.

35 Statistical analyses of release data from batches of tablets subjected to the in vitro dissolution test show that the pattern of drug release from tablets according to

the present invention follows substantially zero-order release kinetics. In other words, the relationship between the amount of drug released and time is linear. This means that the amount of drug available for
5 absorption is fairly constant over a period of time.

The release data from individual replicate tablets is modelled according to the equations representing:

(a) the linear relationship of the amount of drug released (Q) as a function of time (t) in the in
10 vitro dissolution test (Q_{at}) and

(b) the relationship between the amount of drug released (Q) and the square root of time ($\sqrt{t}$) in the in
vitro dissolution test (Q _{α /t})
from start up to a level of at least 70% release from the
15 product in each case.

1. The relative goodness of fit of the experimental results to each of the models is assessed by Pearson's product moment correlation coefficient (r value) for each individual tablet tested.
- 20 2. Each r value is transformed to 'Fisher's Z' value by calculation as follows:

$$25 \quad z = 0.5 \ln \frac{1+r}{1-r}$$

3. The replicate values of 'Z' obtained from the individual tablet dissolution results from the linear and square-root of time relationships are then compared using standard parametric statistical procedures, for example,
30 two sample t tests or the one-way analysis of variance

(ANOVA) test to determine the statistical significance of the difference of the goodness of fit of the experimental data to each of these relationships.

By a linear relationship we mean a relationship in which either or both of the following conditions is satisfied:

a) the arithmetic mean value of Z from replicate drug release results fitted to the linear relationship is greater than the arithmetic mean value of Z from the replicate drug release results fitted to the square-root of time relationship and/or

b) in the t test (or ANOVA) the significance of the difference (one-tailed) is equal to, or less than, a value of $p = 0.5$.

Such a p value represents the situation where there is at least 95% probability that the fit of the experimental release results to the linear model is better than that to the square-root of time model.

The results of the statistical analysis on batch data is tabulated below (Table 3). The batches represent a formulation series containing Eudragit (as the acrylic based polymer) over a range. They also represent development-scale (3300 tablets) up to production-scale (113000 tablets) manufacture: in each case, the results indicate that the goodness of fit of the in vitro release data to the zero-order model is better than to the square-root of time relationship.

TABLE 3

5		Example 1	Example 2	Example 5	Example 3	Example 3	Example 3	Example 4
	Batch size (number of tablets)	3300	113000	113000	3300	3300	56800	3300
	Content of nifedipine (mg/tablet)	30	30	30	30	30	30	30
10	Content of acrylic resin (mg/tablet)	2.5	3.5	4.0	4.5	4.5	4.5	6.4
	Fit to zero-order relationship:							
15	$r =$	0.9973	0.9970	0.9968	0.9967	0.9921	0.9990	0.9960
	$Z =$	3.2984	3.2553	3.2176	3.2030	2.7673	3.8107	3.1032
	Fit to square-root of time relationship:							
20	$r =$	0.9885	0.9810	0.9893	0.9729	0.9617	0.9889	0.9464
	$Z =$	2.5779	2.3222	2.6126	2.1440	1.9678	2.5958	1.7958
	Ratio $\frac{Z_{\text{zero-order}}}{Z_{\text{time}}}$	1.28	1.40	1.23	1.49	1.41	1.47	1.73
25	Significance of difference between Z zero order/Z sq rt time:							
	$p =$	< 0.001	< 0.001	0.013	< 0.001	< 0.001	< 0.001	< 0.001

30

The findings show that it is possible to obtain zero-order drug release from the tablets a) over a range of formulations and b) when producing the tablets either in the laboratory (development-scale batches) or on conventional pharmaceutical production-scale processing plant.

Example 7

Figure 2 illustrates the levels of intact nifedipine, i.e. the drug that has not undergone any form of metabolism and which is present in the blood circulation in the chemical form in which it has been administered, following single doses of 10 mg of an immediately-releasing formulation (labelled as Imm rel caps), or 30 mg in the form of the tablets of Example 3, or in the form of Procardia XL tablets which is a controlled-release nifedipine product marketed in the USA as an osmotically regulated device (labelled as osmotic tab 30 mg).

The blood level vs time profile for the product of Example 3 shows the following advantages:

- i) it shows a prolongation of nifedipine release and absorption into the body compared with the immediately releasing product;
- ii) it does not suffer from the initial lag-time shown by the product which is in the form of an osmotically regulated device, and
- iii) it can provide for controlled release of the nifedipine in a manner which suggests the clinical usefulness of the product when administered once daily.

Example 8

Three sets of granules were manufactured according to (a) Example 2 in a small batch of 3,000 tablets (set 1), (b) Example 2 in a batch of 113,000 tablets (set 2) and (c) Example 3 (except for the drying step) in a batch of 3,300

tablets (set 3). The sets were used in a scanning electron microscopic study. The granules in set 3 were tray dried instead of being fluid bed dried.

The granules were mounted and examined using an ISI 5 100A scanning electron microscope with an accelerating voltage of 10 kv at a working distance of 20mm.

Three fields for each sample were examined at a magnification of x 1250. The results of the magnification in field 1 only are shown in the photomicrographs of Figs. 3 10 to 5 (Fig. 3 = set 1, Fig. 4 = set 2, Fig. 5 = set 3). The other two fields gave a similar appearance. All three sets gave the appearance of standard tablet granules. No nifedipine crystals were seen in any of the fields of view indicating that nifedipine is present in a amorphous phase.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a
5 stated integer or group of integers but not the exclusion of any other integer or group of integers.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A slow-release pharmaceutical composition which comprises particles of a finely divided pharmaceutically acceptable water soluble carrier coated with a mixture of
5 nifedipine with polyvinylpyrrolidone or a copolymer of N-vinylpyrrolidone and vinyl acetate, and a pharmaceutically acceptable acrylic based polymer, the weight ratio of the polyvinylpyrrolidone or N-vinylpyrrolidone and vinyl acetate copolymer to the content of
10 nifedipine being in the range of from 1:1 to 1:10 and the weight ratio of the acrylic based polymer to the content of nifedipine being in the range of from 1:4 to 1:20.
2. A composition according to claim 1 wherein said ratio of the acrylic based polymer to the content of
15 nifedipine is in the range 1:5 to 1:12.
3. A composition according to claim 1 or claim 2 wherein said ratio of the acrylic based polymer to the content of nifedipine in the composition is in the range 1:6 to 1:10.
- 20 4. A composition according to any one of claims 1 to 3 wherein said ratio of the content of polyvinylpyrrolidone or copolymer of N-vinyl-pyrrolidone and vinyl acetate to the content of nifedipine in the composition is in the range 1:2 to 1:8.
- 25 5. A composition according to claim 4 wherein said ratio of the polyvinylpyrrolidone or copolymer of N-vinyl-pyrrolidone and vinyl acetate is in the range 1:2 to 1:5.
6. A composition according to any one of the preceding claims



~~preceding claims~~ wherein the amount of nifedipine released from tablets of the composition in an in vitro dissolution test is related to time by a linear relationship better than by a square-root of time relationship.

- 5 7. A composition according to any any one of the preceding claims wherein the nifedipine is present in amorphous form.
8. A composition according to any one of the preceding claims wherein the pharmaceutically acceptable
- 10 water soluble carrier has a particle size of less than 250 μm .
9. A composition according to any one of the preceding claims wherein the pharmaceutically acceptable water soluble carrier is lactose, sucrose or mannose or a
- 15 mixture of two or more thereof.
10. A composition according to any one of the preceding claims wherein the pharmaceutically acceptable carrier has a surface area of greater than $0.5 \text{ m}^2/\text{g}$.
11. A composition according to any one of the
- 20 preceding claims which is in the form of a solid unit dosage form.
12. A composition according to claim 11 wherein the solid unit dosage form is a tablet or a capsule.
13. A process for the preparation of a pharmaceutical
- 25 composition which contains nifedipine as the active agent, polyvinylpyrrolidone or a copolymer of N-vinyl pyrrolidone and vinyl acetate, and a pharmaceutically acceptable acrylic based polymer, the weight ratio of the polyvi-



nylpyrrolidone or copolymer of N-vinyl-pyrrolidone and vinylacetate to the content of nifedipine being in the range of from 1:1 to 1:10 and the weight ratio of the acrylic based polymer to the content of nifedipine being in
5 the range of from 1:4 to 1:20, which process comprises dissolving nifedipine, polyvinylpyrrolidone or the copolymer of N-vinylpyrrolidone and vinyl acetate, and the pharmaceutically acceptable acrylic based polymer in a suitable solvent to form a solution, coating particles of a
10 finely divided pharmaceutically acceptable water soluble carrier which is insoluble in the solvent with said solution and evaporating the solvent from the coated carrier particles.

14. A process according to claim 13 wherein the water
15 soluble carrier is coated with said solution in stepwise fashion.

15. A process according to claim 13 or 14 wherein the solvent is a lower aliphatic alcohol, methylene chloride or chloroform.

20 16. A process according to any one of claims 13 to 15 wherein the weight ratio of the polyvinylpyrrolidone or copolymer of N-vinylpyrrolidone and vinyl acetate to the content of nifedipine is from 1:2 to 1:5.

17. A process according to any one of claims 13 to 16
25 wherein the coated particles are formed into a solid unit dosage form.

- 26 -

18. Slow-release pharmaceutical compositions or processes for their preparation, substantially as hereinbefore described with reference to the Examples and/or drawings.

5

DATED this 23rd day of February, 1995

Ethical Pharmaceuticals Limited

By Its Patent Attorneys

10 DAVIES COLLISON CAVE



1/4





Fig. 2.



3/4

Fig.3.




Fig.4.



4/4

Fig. 5.



INTERNATIONAL SEARCH REPORT

PCT/GB 93/00055

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K31/44; A61K9/16		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP,A,0 387 782 (EGIS) 19 September 1990 cited in the application see claims see page 4, line 39 - line 43 see page 5, line 17 - line 37 ---	1-17
Y	EP,A,0 410 422 (OTSUKA) 30 January 1991 see claims see column 2, line 55 see column 3, line 9 - line 22 see column 3, line 48 - line 56 see examples 1,4 ---	1-17
Y	EP,A,0 385 582 (ETHICAL PHARMACEUTICALS) 5 September 1990 cited in the application see claims ---	1-17
	--- -/-	
¹⁰ Special categories of cited documents : ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed ^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art ^{"A"} document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 30 MARCH 1993		Date of Mailing of this International Search Report 2. 04. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer SCARPCNI U.

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant pages	Relevant to Claim No.
Y	WO, A, 8 601 717 (PHARMATEC) 27 March 1986 cited in the application see claims -----	1-17

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300055
SA 68731

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 30/03/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0387782	19-09-90	CA-A-	2012194	14-09-90
		CH-A-	680416	31-08-92
		FR-A-	2644343	21-09-90
		GB-A, B	2229095	19-09-90
		JP-A-	2279626	15-11-90
		US-A-	5108757	28-04-92

EP-A-0410422	30-01-91	JP-A-	3130225	04-06-91

EP-A-0385582	05-09-90	AU-B-	626130	23-07-92
		AU-A-	4893790	23-08-90
		JP-A-	2235815	18-09-90
		US-A-	5145683	08-09-92

WO-A-8601717	27-03-86	AU-B-	588258	14-09-89
		AU-A-	4959485	08-04-86
		CA-A-	1253079	25-04-89
		EP-A, B	0226588	01-07-87
		JP-B-	4017932	26-03-92
		JP-T-	62500660	19-03-87
